TuHURA Biosciences ( (HURA) ) has shared an announcement.
On May 5, 2025, TuHURA Biosciences and Kineta, Inc. amended their merger agreement initially signed on December 11, 2024. The amendment outlines changes to the merger consideration, including adjustments to stock and cash considerations based on various financial metrics and liabilities. The completion of the merger is contingent upon a concurrent investment of at least $20 million and has an extended deadline of June 30, 2025. Additionally, TuHURA entered into a separation agreement with its former Chief Scientific Officer, Dennis Yamashita, confirming his termination on December 16, 2024, and detailing severance and stock option terms.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
Average Trading Volume: 211,476
Technical Sentiment Signal: Sell
Current Market Cap: $162.9M
See more data about HURA stock on TipRanks’ Stock Analysis page.